There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To review the use of hCG and to describe the clinical benefit of recombinant hCG (r-hCG)
based on the published results of prospective, randomized studies. Review of published
articles. Tertiary infertility care center.None.None. Oocyte number and quality, luteal
phase progesterone, pregnancy and OHSS rate, and local tolerability. The published
data consistently show that single doses of 250 microg r-hCG and 5,000 IU urinary
(u)-hCG produce similar clinical outcomes when used in infertility treatment cycles
for timed intercourse, IUI, and IVF in terms of the number of oocytes retrieved, number
of mature oocytes harvested, and fertilization and pregnancy rates attained. Single
doses of 10,000 IU u-hCG also gave results comparable to single doses of 250 microg
r-hCG. P levels in the midluteal phase were significantly higher with the use of r-hCG
compared with u-hCG, and local injection site adverse effects were significantly less
frequent, demonstrating the higher purity of the recombinant product. A single 500-microg
dose of r-hCG led to a higher rate of ovarian hyperstimulation syndrome compared with
a 250-microg dose, with no significant improvement in pregnancy rates.A single dose
of 250 microg r-hCG was at least as effective as single doses of 5,000 or 10,000 IU
u-hCG but offered the advantages associated with use of a recombinant product: local
injection site adverse effects were significantly less frequent with r-hCG than with
u-hCG.